Trials / Completed
CompletedNCT00002095
A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 700 (planned)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 13 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of oral ganciclovir in preventing progression to cytomegalovirus (CMV) disease (e.g., CMV retinitis, gastrointestinal CMV disease) in CMV-infected people with HIV infection and CD4 lymphocyte counts \<= 100 cells/mm3. To evaluate the efficacy of this drug in reducing morbidity associated with coinfection by both CMV and HIV.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ganciclovir |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
19 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002095. Inclusion in this directory is not an endorsement.